A Multicenter and Observational Study to Assess the Effectiveness of Infliximab Comparing With Conventional Therapy in Ankylosing Spondylitis Subjects With Hip Involvement

Trial Profile

A Multicenter and Observational Study to Assess the Effectiveness of Infliximab Comparing With Conventional Therapy in Ankylosing Spondylitis Subjects With Hip Involvement

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Infliximab (Primary) ; Disease-modifying antirheumatics; Nonsteroidal anti-inflammatories
  • Indications Ankylosing spondylitis
  • Focus Therapeutic Use
  • Acronyms RECOVERY
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 13 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Jun 2017 Biomarkers information updated
    • 19 Apr 2017 Planned End Date changed from 13 Apr 2018 to 15 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top